ImmoTest-I™

Advanced Body Defense Mapping Test

ImmoTest-I™ is an advanced blood-based immune profiling test designed to assess immune activation, immune suppression, and immune readiness in cancer-related clinical planning.

The immune system plays an important role in cancer surveillance, treatment response, and overall patient resilience. However, not every patient has the same immune condition. Some patients may show strong immune activation, while others may show signs of immune suppression, immune exhaustion, chronic inflammation, or immune imbalance.

ImmoTest-I™ helps provide a clearer picture of the patient’s immune status, allowing doctors to better understand whether the immune system is ready, suppressed, or imbalanced before planning immune-related oncology support.

WHAT IMMOTEST-I™ IS?

ImmoTest-I™ is an immune profiling test that evaluates selected immune markers, cytokines, and immune-cell activity patterns from a blood sample.

It is designed to help medical professionals understand the patient’s immune condition, especially in cases where immune-based support or precision oncology planning may be considered.

ImmoTest-I™ helps map how the immune system is behaving.

It provides information about immune activation and immune suppression, which may help support professional decision-making.

HOW IMMOTEST-I™ WORKS?

ImmoTest-I™ analyses the immune system from multiple angles.

The test may evaluate immune-related markers linked to:

• B-cell activity
• T-cell activity
• cytotoxic immune response
• helper immune response
• immune suppression
• regulatory immune pathways
• antigen-presenting cell activity
• inflammatory and anti-inflammatory signalling
• immune readiness

Based on the sample report, the laboratory process includes serum isolation from whole blood, ELISA testing for immune activation/suppression cytokines, and flow cytometry for selected immune-cell markers.

By reviewing these markers together, ImmoTest-I™ provides a structured immune profile that may help doctors assess whether the patient’s immune system is activated, suppressed, or imbalanced.

WHAT MAKES IMMOTEST-I™ DIFFERENT?

• Immune-Readiness Focused
  • ImmoTest-I™ helps assess whether the patient’s immune system may be suitable for immune-related oncology support planning.
• Activation and Suppression Profiling
  • It reviews both immune activation and immune suppression, instead of only giving a general “immune strength” impression.
• Supports Personalized Planning
  • The result may help doctors decide whether immune-related support is appropriate, needs to be delayed, or requires further evaluation.
• Useful Before Immune-Based Support
  • ImmoTest-I™ may be useful before considering approaches that depend on immune recognition, immune response, or immune readiness.
• Professional Decision-Support Tool
  • It is designed to support medical interpretation and clinical planning, not to replace specialist consultation.

KEY BENEFITS

• Maps Immune Status
  • Provides a structured overview of immune activation, suppression, and immune balance.
• Supports Suitability Assessment
  • Helps doctors assess whether immune-related support may be suitable for the patient.
• Provides Deeper Case Understanding
  • Gives additional insight into the patient’s immune condition beyond routine blood tests.
• Supports Personalized Oncology Planning
  • Helps align the support strategy with the patient’s actual immune profile.
• Helps Identify Immune Suppression
  • May help detect patterns of immune down-regulation or immune imbalance that require professional attention.
• Useful for Ongoing Monitoring
  • May support immune-status review during cancer management, follow-up, or advanced oncology planning.

WHO IMMOTEST-I™ IS DESIGNED FOR?

ImmoTest-I™ is designed for patients who require deeper immune assessment as part of professional oncology planning.

It may be considered for patients who:

• have a confirmed cancer diagnosis
• are being considered for immune-related support
• require immune-readiness assessment
• have complex cancer cases
• are undergoing advanced oncology planning
• need immune activation or suppression profiling
• require better understanding of immune status
• may be considered for tumour-recognition or immune-support strategies

Suitability and interpretation should always be guided by qualified healthcare professionals.

WHEN IMMOTEST-I™ MAY BE RECOMMENDED?

ImmoTest-I™ may be considered before:

• immune-related oncology support
• personalised cancer support planning
• tumour-recognition support strategies
• advanced oncology monitoring
• combination support programs
• doctor-led cancer management review
• immune-readiness evaluation

It may also be used when doctors need a clearer understanding of whether the patient’s immune system is activated, suppressed, or imbalanced.

WHAT THE RESULT MAY SHOW?

ImmoTest-I™ may provide information related to:

• immune activation
• immune suppression
• cytokine activity
• T-cell activity
• B-cell activity
• cytotoxic immune response
• helper immune response
• regulatory immune activity
• antigen-presenting cell function
• immune balance

The sample report includes markers such as CD19, CD20, CD28, CD62L, IFN-γ, IL-4, IL-6, IL-2, TNF-α, CD25, CTLA4, CD80, and CD86. These are immune-related markers used to support immune activation/suppression profiling.

HOW RESULTS SHOULD BE USED?

ImmoTest-I™ results should be interpreted by qualified medical professionals.

The result should be reviewed together with:

• cancer diagnosis
• imaging reports
• blood investigations
• treatment history
• current medications
• immune-related conditions
• performance status
• symptoms
• overall patient condition

The test does not provide a treatment decision by itself. It supports better clinical understanding and professional case planning.

IMPORTANT NOTICE

ImmoTest-I™ is an immune profiling test. It is not intended to diagnose cancer, treat cancer, cure cancer, or prevent cancer.

Results must be interpreted by qualified medical professionals and reviewed together with the patient’s clinical history, imaging, laboratory findings, treatment status, and overall medical condition.

ImmoTest-I™ is designed to support immune-status assessment and personalized oncology planning, not to replace oncology consultation or standard medical care.